Increased neopterin concentration in patients with primary arterial hypertension

  • Artur Cieślewicz Deprtment of Clinical Pharmacology, Poznan University of Medical Sciences, Poland
  • Katarzyna Korzeniowska Deprtment of Clinical Pharmacology, Poznan University of Medical Sciences, Poland
  • Paweł Bogdański Department of Internal Medicine, Metabolic Disorders and Hypertension, Poznan University of Medical Sciences, Poland
  • Anna Jabłecka Deprtment of Clinical Pharmacology, Poznan University of Medical Sciences, Poland
Keywords: neopterin, hypertension, inflammation

Abstract

The data on the safety profile of anti-tumor necrosis factor (anti-TNF) therapy in real-life patients cohorts with in flammatory bowel disease (IBD) still are lacking. Neopterin is a pteridine derivative produced from guanosine triphosphate mainly by activated monocytes and macrophages in response to cytokines produced by T-lymphocytes and natural killer cells. Changes in neopterin level reflect the stage of activation of cellular immune system and can be associated with various diseases. Low-grade inflammation is also an important factor in the pathophysiology of hypertension. In presented study we assessed neopterin concentration in 63 patients with primary arterial hypertension compared to 14 control healthy volunteers. Obtained results confirmed increased neopterin level in patients group.